Mirdametinib in Histiocytic Disorders

NCT06153173 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Langerhans Cell Histiocytosis (LCH)
Juvenile Xanthogranuloma (JXG)
Rosai-Dorfman Disease (RDD)
Histiocytic Disorders

Interventions

DRUG: Mirdametinib

Sponsor

Children's Hospital Medical Center, Cincinnati